1372256-52-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-amino-6-tert-butoxycarbonylaminohexanoic acid methyl ester is used as a key component in the production of pharmaceuticals and peptide-based drugs for its ability to improve the stability and activity of these compounds.
Used in Drug Development:
(R)-2-amino-6-tert-butoxycarbonylaminohexanoic acid methyl ester is used as a building block for the synthesis of various peptide-based molecules, playing a crucial role in the development of new drugs and the modification of existing ones to enhance their efficacy.
Used in Research and Development:
(R)-2-amino-6-tert-butoxycarbonylaminohexanoic acid methyl ester is used as a unique chemical compound in the research and development of new drug formulations, due to its distinctive properties that contribute to the advancement of pharmaceutical innovation.

Upstream product

• 327026-75-5 Psoc-Lys(Boc)-OMe 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 92122-45-7 Fmoc-D-Lys(BOC)-OH 
• 172846-57-0 C₂₇H₃₄N₂O₆ 
• 66845-42-9 N^α-(benzyloxycarbonyl)-N^ε-(tert-butoxycarbonyl)-D-lysine 
• 84559-78-4 methyl (2R)-2-[[(benzyloxy)carbonyl]amino]-6-[[(tert-butoxy)carbonyl]amino]hexanoate 
• 67-56-1 methanol 
• 2418-95-3 (S)-2-amino-6-(tert-butoxycarbonylamino)hexanoic acid 
• 657-27-2 L-Lysine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 13515-95-2 lysine methyl ester dihydrochloride 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 
• 2212-76-2 N^α-benzyloxycarbonyl-N^ε-tert-butyloxycarbonyl-L-lysine dicyclohexylamine salt 
• 14511-39-8 2(S)-2-amino-6-(benzylideneamino)hexanoic acid 

Downstream Products

• 100603-66-5 (S)-2-((R)-1-Benzyloxycarbonyl-ethylamino)-6-tert-butoxycarbonylamino-hexanoic acid methyl ester 
• 3236-14-4 N-Z-L-Seryl-N^ε-BOC-L-lysinmethylester 
• 247202-80-8 2-(4-benzyloxy-benzylamino)-6-tert-butoxycarbonylamino-hexanoic acid methyl ester 
• 1204605-12-8 for-Met-Leu-Phe-Lys[γ-Asp(OMe)-Phe-Leu-Met-for]-OMe 
• 1204605-15-1 for-Met-Leu-Phe-Lys(Phe-Leu-Met-for)-Lys(Phe-Leu-Met-for)-OMe 
• 1204605-13-9 for-Met-Leu-Phe-Lys(Phe-Leu-Met-for)-OMe 
• 132903-67-4 Arg-Lys-Asp-Val-Tyr tris trifluoroacetate 

Relevant academic research and scientific papers

Synthesis of lysine-containing fragments of the Proteus mirabilis O27 O-specific polysaccharide and neoglycoconjugates therefrom

Amide-linked lysine mono- and di-uronic acid fragments of the O-specific polysaccharide from P. mirabilis O27 have been synthesised.Nε-Boc-L-lysine tert-butyl ester was condensed with 2-azidoethyl glycosides of glucuronic acid and β-D-GlcpNAc-(1->3)-β-D-GlcpA.Transformation of the products into 2-acrylamidoethyl glycosides, followed by deprotection using trifluoroacetic acid, gave the target monomers that were converted into high-molecular-weight copolymer-type neoglycoconjugates.

Investigating a Boronate-Affinity-Guided Acylation Reaction for Labelling Native Antibodies

The excellent molecular recognition capabilities of monoclonal antibodies (mAbs) have opened up exciting opportunities for biotherapeutic discovery. Taking advantage of the full potential of this tool necessitates affinity ligands capable of conjugating directly with small molecules to a defined degree of biorthogonality, especially when modifying natural Abs. Herein, a bioorthogonal boronate-affinity-based Ab ligand featuring a 4-(dimethylamino)pyridine and an S-aryl thioester to label full-length Abs is reported. The photoactivatable linker in the acyl donor facilitated purification of azide-labelled Ab (N3-Ab) was quantitatively cleaved upon brief exposure to UV light while retaining the original Ab activity. Click reactions enabled the precise addition of biotin, a fluorophore, and a pharmacological agent to the purified N3-Abs. The resulting immunoconjugate showed selectivity against targeted cells. Bioorthogonal traceless design and reagentless purification allow this strategy to be a powerful tool to engineer native antibodies amenable to therapeutic intervention.

De novo Design of SARS-CoV-2 Main Protease Inhibitors

The COVID-19 pandemic prompted many scientists to investigate remedies against SARS-CoV-2 and related viruses that are likely to appear in the future. As the main protease of the virus, M Pro, is highly conserved among coronaviruses, it has emerged as a prime target for developing inhibitors. Using a combination of virtual screening and molecular modeling, we identified small molecules that were easily accessible and could be quickly diversified. Biochemical assays confirmed a class of pyridones as low micromolar noncovalent inhibitors of the viral main protease.

Epoc group: Transformable protecting group with gold(iii)-catalyzed fluorene formation

This study presents the novel concept of a transformable protecting group, which changes its properties through structural transformation. Based on this concept, we developed a 2-(2-ethynylphenyl)-2-(5-methylfuran-2-yl)-ethoxycarbonyl (Epoc) group. The Epoc group was transformed into an Fmoc-like structure with gold(iii)-catalyzed fluorene formation and was removable under Fmoc-like mild basic conditions post-transformation even though it was originally stable under strongly basic conditions. As an application for organic synthesis, the Epoc group provides the novel orthogonality of gold(iii)-labile protecting groups in solid-phase peptide synthesis. In addition, the high turnover number of fluorene formation in aqueous media is suggestive of the applicability of the Epoc group to biological systems. This journal is

FACTOR XIIa INHIBITORS

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.

Serine- and threonine-derived diamine equivalents for site-specific incorporation of platinum centers in peptides, and the anticancer potential of these conjugates

A modular strategy that allows introduction of one or more reactive platinum units at chosen locations along a peptide sequence is presented. This makes use of diazides generated from serine and threonine as diamine equivalents which can be conjugated to the peptide under standard coupling conditions. Reduction of these diazides using Pd/C and H2 followed by platination affords the final products in good yields. Following this, we prepared a new class of peptide-platinum conjugates and carried out preliminary cytotoxicity evaluation and DNA interaction studies. Inclusion of lysine residues in the sequence was found to improve DNA interaction and anticancer activities compared to analogous conjugates with hydrophobic side chains.

KETONE INHIBITORS OF LYSINE GINGIPAIN

The present invention provides compounds according to Formula (I) as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

Simple and efficient Fmoc removal in ionic liquid

A mild method for an efficient removal of the fluorenylmethoxycarbonyl (Fmoc) group in ionic liquid was developed. The combination of a weak base such as triethylamine and [Bmim][BF4] makes the entire system more efficient for the cleavage at room temperature of various amines and amino acid methyl esters in short reaction times. The procedure works well even in the case of N-Fmoc amino acids bearing acid-sensitive protecting groups and of N-alkylated amino acid methyl esters. The solvent-free condition provides a complementary method for Fmoc deprotection in solution phase peptide synthesis and modern organic synthesis.

Radical arylation of tyrosine residues in peptides

The radical arylation of the phenolic side chain of tyrosine in peptides was investigated. Aryl radicals were generated from aryldiazonium salts using titanium(III) chloride as stoichiometric reductant. Due to the high selectivity with which 3-aryltyrosine derivatives were formed, this reaction type represents a new strategy for the direct functionalization of peptides.

Synthesis and antibacterial activities of amphiphilic neomycin B-based bilipid conjugates and fluorinated neomycin B-based lipids

Investigating the effect of lipid hydrophobicity on the activity of amphiphilic neomycin B conjugates, six polycationic amphiphiles (PAs) were created. Four of the new compounds incorporated either palmitic or arachidic di-lipid lysine tails, while two had single fluorinated undecanoic acid tails. The basicity of half of the compounds was increased through the incorporation of six guanidine moieties, in order to assess the effect of base strength on antimicrobial activity. A panel of ten bacteria was used for the testing, with seven strains obtained from the American Type Culture Collection series and three clinical isolates from Canadian Intensive Care Units. When compared to previous results with hydrocarbon monolipids the PAs all compounds were found to have reduced activity, though the hemolytic activity of the compounds with fluorinated tails was sharply reduced, with only a moderate reduction in antimicrobial activity.